(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
5 August 2010 (05.08.2010)

PCT

(10) International Publication Number
WO 2010/086259 A1

(51) International Patent Classification:
*C07D 401/12* (2006.01) *A61P 25/24* (2006.01)
*C07D 401/14* (2006.01) *A61P 25/04* (2006.01)
*C07D 413/14* (2006.01) *A61P 25/18* (2006.01)
*A61K 31/454* (2006.01) *A61P 25/16* (2006.01)
*A61K 31/4545* (2006.01) *A61P 25/22* (2006.01)

(21) International Application Number:
PCT/EP2010/050591

(22) International Filing Date:
19 January 2010 (19.01.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09151722.7 30 January 2009 (30.01.2009) EP

(71) Applicant *(for all designated States except US)*: **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, CH-4070 Basel (CH).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **KNUST, Henner** [DE/DE]; Im Ortsetter 26a, 79618 Rheinfelden (DE). **NETTEKOVEN, Matthias** [DE/DE]; Ruetteweg 3, 79639 Grenzach-Wyhlen (DE). **RATNI, Hasane** [FR/FR]; Louis Pasteur 4, F-68440 Habsheim (FR). **RIEMER, Claus** [DE/DE]; Dreikoenigstrasse 31, 79102 Freiburg (DE). **VIFIAN, Walter** [CH/CH]; Saegegasse 1, CH-4460 Gelterkinden (CH).


(74) Agent: **POPPE, Regina**; Grenzacherstrasse 124, CH-4070 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


**Published**:
— *with international search report (Art. 21(3))*

(54) **Title**: PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS



(I)

A=



a) b) c)

(57) **Abstract**: The present invention relates to a compounds of formula (I) wherein $Ar^1$ is aryl or a six membered heteroaryl; $Ar^2$ is aryl or a six membered heteroaryl; $R^1$ is hydrogen, halogen, lower alkyl, lower alkoxy or lower alkyl substituted by halogen; $R^2$ is hydrogen, halogen, lower alkyl, lower alkyl substituted by halogen or cyano; $R^3$ is hydrogen or lower alkyl; $R^4$ is hydrogen, lower alkyl, phenyl, optionally substituted by halogen, or is a five membered heteroaryl, optionally substituted by lower alkyl, or is aryl optionally substituted by halogen; is a six membered heterocyclic group, wherein X is $-N(SO_2CH_3)$; $R^6$ is hydrogen; Y is $-N(R^7)-$ $R^7$ is a 6-membered heteroaryl group, optionally substituted by cyano or C(O)-cycloalkyl, wherein the cycloalkyl group is optionally substituted by lower alkyl, n is 1; m is 1; o is1; p is 1; s is 0; t is 1; u is 1; or to a pharmaceutically active salt, a racemic mixture, an enantiomer, an optical isomer or a tautomeric form thereof. It has been found that the present compounds are high potential NK-3 receptor antagonist for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia anxiety and attention deficit hyperactivity disorder (ADHD).

WO 2010/086259 A1